Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.(600196),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

600196 Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.

Closed 07-01 15:00:00

23.12

+0.65

+2.89%

High23.19	Low21.90	Vol45.12M
Open22.21	D1 Closing22.47	Amplitude5.74%
Mkt Cap61.73B	Tradable Cap48.97B	Total Shares2.67B
T/O1.02B	T/O Rate2.13%	Tradable Shares2.12B
P/B1.26	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"600196","market":"SH","secType":"STK","nameCN":"Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.","latestPrice":23.12,"timestamp":1782889200000,"preClose":22.47,"halted":0,"volume":45117625,"delay":0,"changeRate":0.0289,"floatShares":2118000000,"shares":2670000000,"eps":1.3019,"marketStatus":"Closed","change":0.65,"latestTime":"07-01 15:00:00","open":22.21,"high":23.19,"low":21.9,"amount":1024000000,"amplitude":0.0574,"askPrice":23.12,"askSize":1119,"bidPrice":23.11,"bidSize":1391,"shortable":0,"etf":0,"ttmEps":1.3019,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1782955800000},"marketStatusCode":5,"adr":0,"adjPreClose":22.47,"symbolType":"stock","openAndCloseTimeList":[[1782869400000,1782876600000],[1782882000000,1782889200000]],"highLimit":24.72,"lowLimit":20.22,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":2670429325,"isCdr":false,"pbRate":1.26,"roa":"--","peRate":17.75866,"roe":"1.78%","epsLYR":1.27,"committee":-0.229234,"marketValue":61740000000,"turnoverRate":0.0213,"status":0,"nextConnectDate":"Northbound have stopped. The next trading day is UTC+8 2026-07-02.","hkstockBrief":{"symbol":"02196","market":"HK","secType":"STK","nameCN":"FOSUN PHARMA","latestPrice":15.11,"timestamp":1782806887004,"preClose":15.66,"halted":0,"volume":6495138,"delay":0,"premium":"-43.39"},"floatMarketCap":48979000000},"requestUrl":"/m/hq/s/600196/tweets","defaultTab":"tweets","newsList":[{"id":"2648170505","title":"Junshi Biosciences Licenses JS005 Rights in Greater China to Fosun Wanbang for CNY 215 Million Upfront","url":"https://stock-news.laohu8.com/highlight/detail?id=2648170505","media":"Reuters","labels":["shareholding","corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648170505?lang=en_us&edition=fundamental","pubTime":"2026-07-01 19:28","pubTimestamp":1782905285,"startTime":"0","endTime":"0","summary":"Junshi Biosciences licenses JS005 rights in Greater China to Fosun Wanbang for CNY 215 million upfrontShanghai Junshi Biosciences signed a Greater China licensing deal with Fosun Pharma unit Fosun Wan","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260701:nNDL6MGfg3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0188","688180","600196","BK0012","00656","BK1230","BK0196","BK0175","BK0239","BK0183","BK0060","BK0028","BK0096","BK0187"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648551552","title":"Shanghai Fosun Pharmaceutical Says Board Approved Appointment of Xingli Wang as President","url":"https://stock-news.laohu8.com/highlight/detail?id=2648551552","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648551552?lang=en_us&edition=fundamental","pubTime":"2026-07-01 16:18","pubTimestamp":1782893891,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260701:nL4N4330ML:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK0188","BK0060","BK0028","BK0196","BK0012","600196","BK0096","BK0183","BK0175","BK0187","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648515261","title":"Shanghai Fosun Pharmaceutical's Board Approves President Appointment","url":"https://stock-news.laohu8.com/highlight/detail?id=2648515261","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648515261?lang=en_us&edition=fundamental","pubTime":"2026-07-01 16:18","pubTimestamp":1782893891,"startTime":"0","endTime":"0","summary":"BRIEF-Shanghai Fosun Pharmaceutical's Board Approves President AppointmentJuly 1 (Reuters)-Shanghai Fosun Pharmaceutical Group Co Ltd600196.SS:SAYS BOARD APPROVED APPOINTMENT OF XINGLI WANG AS PRESIDENTSource textFurther company coverage:600196.SS","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260701:nL4N4330ML:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0175","BK0188","BK0196","BK0096","600196","BK0183","BK0239","BK0012","BK0028","BK0187","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647858019","title":"Fosun Pharma to Offload Partnership Fund Stake for 1 Million Yuan; Shares Down 4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2647858019","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647858019?lang=en_us&edition=fundamental","pubTime":"2026-06-30 14:59","pubTimestamp":1782802785,"startTime":"0","endTime":"0","summary":"Shanghai Fosun Pharmaceutical  and a subsidiary agreed to dispose of their stake in Jinan Fujian Partnership to Shanghai Fujian, according to a Shanghai bourse filing on Tuesday.Fosun will transfer its subscribed 7 million yuan interest in the partnership fund for 1.1 million yuan, while its subsidiary, Fosun Pingyao, will transfer its 1 million yuan stake for 150,000 yuan.After the transaction, the company will no longer own any equity in Jinan Fujian.The pharmaceutical company's Hong Kong shares dropped 4%, while Shanghai shares fell nearly 2% during the afternoon trade.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1191","600196","BK0060","BK0175","BK0239","BK1515","BK0183","BK0196","BK0188","BK1593","BK0096","02196","BK0012","BK0187","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647837610","title":"Fosun Pharma's Unit Gets Registration Nod for Spasm, Pain Drug in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2647837610","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647837610?lang=en_us&edition=fundamental","pubTime":"2026-06-29 19:30","pubTimestamp":1782732638,"startTime":"0","endTime":"0","summary":"Shanghai Fosun Pharmaceutical's  unit Hebei Wanbang Folon Pharmaceutical obtained approval for the registration application of Shaoyao Gancao Tang Granules from China's National Medical Products Administration.The drug is used for various spasm and pain conditions caused by insufficiency of yin and blood and malnourishment of the sinews and vessels that manifests as leg and feet spasms andabdominal pain, according to a Monday filing.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["02196","BK0096","BK0175","BK0183","BK0239","600196","BK0188","BK0187","BK0012","BK0060","BK0196","BK1515","BK1191","BK0028","BK1593"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647997378","title":"Shanghai Fosun Pharma - Drug Registration Application for Shaoyao Gancao Tang Granules Approved by Nmpa","url":"https://stock-news.laohu8.com/highlight/detail?id=2647997378","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647997378?lang=en_us&edition=fundamental","pubTime":"2026-06-29 18:05","pubTimestamp":1782727533,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260629:nFWN4310JO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK0096","BK1191","BK0060","BK0183","BK0028","BK0187","BK0239","BK0012","BK1593","BK0196","02196","BK1515","BK0175","BK0188","600196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1196896333","title":"Fosun Pharma's Subsidiary Gains Approval for Shaoyao Gancao Tang Granules","url":"https://stock-news.laohu8.com/highlight/detail?id=1196896333","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1196896333?lang=en_us&edition=fundamental","pubTime":"2026-06-29 17:58","pubTimestamp":1782727131,"startTime":"0","endTime":"0","summary":"Shanghai Fosun Pharmaceutical (Group) Co.,Ltd. (600196.SH) has announced that its subsidiary, Hebei Wanbang Fulin Pharmaceutical Co., Ltd., has received approval from the National Medical Products...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0196","BK0175","BK1191","600196","BK0183","BK1593","BK1515","BK0188","BK0096","BK0028","02196","BK0187","BK0060","BK0239","BK0012"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647832497","title":"Sinopharm Group Stock Rises 2.3% in Hong Kong","url":"https://stock-news.laohu8.com/highlight/detail?id=2647832497","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647832497?lang=en_us&edition=fundamental","pubTime":"2026-06-29 16:32","pubTimestamp":1782721920,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of Sinopharm Group Co. Ltd. rose 2.3% to 16.16 Hong Kong dollars on what proved to be an all-around positive trading session for the Hong Kong stock market, with the Hang Seng Index rising 1.6% to 23026.68.Sinopharm Group Co. Ltd. closed 28% below its 52-week high of HK$22.34, which the company reached Feb. 25.The stock underperformed when compared to some of its competitors, as Shanghai Fosun Pharmaceutical  Co. Ltd. rose 4.0%.Trading volume totaled 7.8 million shares, compared to the 50-day average of 6.6 million shares.Data source: Dow Jones Market Data, FactSet Dow Jones NewswiresJune 29, 2026 04:32 ET Copyright  2026 Dow Jones & Company, Inc.","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","01099","BK1191","BK0188","BK0187","BK4175","BK1593","LU1115378108.SGD","BK0028","600196","BK1197","BK1500","BK0060","BK0012","LU0640798160.USD","02196","BK0183","BK1515","BK0096","SHTDY","BK0175","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647408823","title":"Fosun Pharma's Vaccine Unit Submits Hong Kong Listing Application","url":"https://stock-news.laohu8.com/highlight/detail?id=2647408823","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647408823?lang=en_us&edition=fundamental","pubTime":"2026-06-29 11:29","pubTimestamp":1782703744,"startTime":"0","endTime":"0","summary":"Shanghai Fosun Pharmaceutical's  vaccine unit, Fosun Adgenvax, has submitted an application for a Hong Kong listing, according to a Friday Hong Kong bourse filing.The company plans to issue H-shares representing no more than 25% of its enlarged share capital, with an overallotment option of up to 15% of the initial offering size.Fosun Pharma said Fosun Adgenvax is expected to remain a subsidiary after the listing.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0096","BK1191","BK0060","BK0183","BK0028","BK0187","BK0239","BK0012","BK1593","BK0196","02196","BK1515","BK0175","BK0188","600196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646535177","title":"Fosun Pharma Unit Fosun Adgenvax Files for Hong Kong IPO in Proposed Spin-off Listing","url":"https://stock-news.laohu8.com/highlight/detail?id=2646535177","media":"Reuters","labels":["shareholding","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646535177?lang=en_us&edition=fundamental","pubTime":"2026-06-26 19:21","pubTimestamp":1782472883,"startTime":"0","endTime":"0","summary":"Fosun Pharma unit Fosun Adgenvax files for Hong Kong IPO in proposed spin-off listingFosun International filed for a spin-off listing of Fosun Adgenvax, a Fosun Pharma subsidiary, on Hong Kong’s Main ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260626:nNDL32WDGP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0028","BK0187","BK0175","BK0012","600196","BK0096","BK0188","BK0239","BK1230","BK0196","00656","BK0183","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121357117","title":"Fosun Pharma Seeks Approval to List Subsidiary Fosun Antigen on Hong Kong Main Board","url":"https://stock-news.laohu8.com/highlight/detail?id=1121357117","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1121357117?lang=en_us&edition=fundamental","pubTime":"2026-06-26 18:46","pubTimestamp":1782470808,"startTime":"0","endTime":"0","summary":"Fosun Pharma has announced that the company and its controlling shareholder, Fosun International Limited, have submitted a joint application to the Stock Exchange of Hong Kong (SEHK) pursuant to...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["600196","BK1593","BK0060","BK0175","BK0196","BK0239","HEXmain","02196","BK1191","BK0187","BK0096","BK0012","BK1515","BK0028","IPOS","BK0188","BK0183"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646599123","title":"Shanghai Fosun Pharma - Co was Informed That Fosun Adgenvax Submitted Listing Application for Listing of Its H Shares on HKEX Main Board","url":"https://stock-news.laohu8.com/highlight/detail?id=2646599123","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646599123?lang=en_us&edition=fundamental","pubTime":"2026-06-26 18:43","pubTimestamp":1782470638,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260626:nFWN42X0W7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK0028","BK0175","BK0196","BK1515","BK0188","BK0239","BK0012","BK1191","BK0187","BK0096","BK1593","02196","BK0183","BK0060","600196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646356717","title":"Shanghai Fosun Pharma's Unit Submits Application for Hong Kong Listing","url":"https://stock-news.laohu8.com/highlight/detail?id=2646356717","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646356717?lang=en_us&edition=fundamental","pubTime":"2026-06-26 18:23","pubTimestamp":1782469394,"startTime":"0","endTime":"0","summary":"BRIEF-Shanghai Fosun Pharma's Unit Submits Application For Hong Kong ListingJune 26 (Reuters)-Shanghai Fosun Pharmaceutical Group Co Ltd600196.SS:SAYS UNIT SUBMITTED APPLICATION FOR HONG KONG LISTINGSource textFurther company coverage:600196.SS","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260626:nL4N42Y0MT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0187","BK0183","BK0096","BK0196","BK0012","BK0239","BK0175","600196","BK0060","BK0188","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646356210","title":"Shanghai Fosun Pharma Says Unit Submitted Application for Hong Kong Listing","url":"https://stock-news.laohu8.com/highlight/detail?id=2646356210","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646356210?lang=en_us&edition=fundamental","pubTime":"2026-06-26 18:23","pubTimestamp":1782469394,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260626:nL4N42Y0MT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK0187","BK0183","BK0239","BK0175","BK0012","BK0060","BK0028","BK0096","BK0188","600196","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645893719","title":"Sinopharm Group Stock Advances 1.1% in Hong Kong","url":"https://stock-news.laohu8.com/highlight/detail?id=2645893719","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645893719?lang=en_us&edition=fundamental","pubTime":"2026-06-24 16:33","pubTimestamp":1782289980,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of Sinopharm Group Co. Ltd. advanced 1.1% to 15.76 Hong Kong dollars on what proved to be an all-around great trading session for the Hong Kong stock market, with the Hang Seng Index rising 0.3% to 23412.18.The stock's rise snapped a four-day losing streak.Sinopharm Group Co. Ltd. closed 29% below its 52-week high of HK$22.34, which the company reached Feb. 25.The stock outperformed some of its competitors, as Shanghai Fosun Pharmaceutical  Co. Ltd. rose 0.1%.Trading volume totaled 6.5 million shares, compared to the 50-day average of 6.3 million shares.Data source: Dow Jones Market Data, FactSet Dow Jones NewswiresJune 24, 2026 04:33 ET Copyright  2026 Dow Jones & Company, Inc.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["600196","BK0187","BK0175","BK1515","BK1197","BK0196","BK1191","02196","BK0183","BK0028","LU1115378108.SGD","BK1500","BK0239","BK1593","BK4175","BK0060","BK0188","01099","SHTDY","LU0640798160.USD","BK0096","BK0012"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645000045","title":"Shanghai Fosun Pharmaceutical Guarantees 249 Million Yuan Loan for Subsidiary","url":"https://stock-news.laohu8.com/highlight/detail?id=2645000045","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645000045?lang=en_us&edition=fundamental","pubTime":"2026-06-23 13:36","pubTimestamp":1782192975,"startTime":"0","endTime":"0","summary":"Shanghai Fosun Pharmaceutical  provided a joint liability guarantee of 248.6 million yuan for wholly-owned subsidiary Fosun Pharma Industry's 84-month loan from China Everbright Bank.The guarantee, effective June 22, falls within the company's 35 billion yuan guarantee limit, according to a Monday filing with the Shenzhen bourse.Shares of the pharmaceutical company rose 1% in recent trade.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0196","BK0187","BK0060","BK0175","BK0012","BK0183","BK0188","BK0239","600196","BK0096","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644705215","title":"Sinopharm Group  Stock Falls 2.7% in Hong Kong","url":"https://stock-news.laohu8.com/highlight/detail?id=2644705215","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644705215?lang=en_us&edition=fundamental","pubTime":"2026-06-18 16:32","pubTimestamp":1781771520,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of Sinopharm Group Co. Ltd. shed 2.7% to 16.38 Hong Kong dollars on what proved to be an all-around poor trading session for the Hong Kong stock market, with the Hang Seng Index falling 1.6% to 23924.81.This was the stock's second consecutive day of losses.Sinopharm Group Co. Ltd. closed 27% below its 52-week high of HK$22.34, which the company achieved Feb. 25.The stock underperformed when compared to some of its competitors, as Shanghai Fosun Pharmaceutical  Co. Ltd. fell 0.1%.Trading volume totaled 7.5 million shares, compared to the 50-day average of 6.2 million shares.","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1115378108.SGD","02196","BK0188","01099","BK0183","BK1500","BK1593","BK1197","BK0175","BK0196","BK0028","BK0239","BK0012","BK0096","600196","BK0060","BK0187","BK4175","SHTDY","BK1191","BK1515","LU0640798160.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644771187","title":"Fosun Pharma Unit Passes GMP Inspection","url":"https://stock-news.laohu8.com/highlight/detail?id=2644771187","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644771187?lang=en_us&edition=fundamental","pubTime":"2026-06-18 12:19","pubTimestamp":1781756374,"startTime":"0","endTime":"0","summary":"Shanghai Fosun Pharmaceutical's  subsidiary, Shanghai Henlius Biotech , passed a drug GMP or good manufacturing practice inspection, according to a Shanghai bourse filing on Thursday.The Shanghai Municipal Medical Products Administration made the inspection at Henlius' manufacturing facility in Songjiang District, which produces the breast cancer drug Hanbeiyou or pertuzumab injection.The company was found to be compliant with GMP requirements.The pharmaceutical company's Shanghai shares rose 2% during the morning trade.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0028","BK0183","HK0000306685.HKD","BK1161","BK0096","BK0239","HK0000320264.USD","BK0188","BK1593","600196","BK0196","BK0187","HK0000165453.HKD","BK0060","HK0000306701.USD","BK1191","BK0175","BK1515","02196","02696","BK0012","HK0000320223.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644779042","title":"Fosun Pharma Gets China Nod to Trial HLX3902 Injection","url":"https://stock-news.laohu8.com/highlight/detail?id=2644779042","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644779042?lang=en_us&edition=fundamental","pubTime":"2026-06-18 11:52","pubTimestamp":1781754725,"startTime":"0","endTime":"0","summary":"Shanghai Fosun Pharmaceutical , through its subsidiary Shanghai Henlius Biotech , received approval from China's National Medical Products Administration for the clinical trials of HLX3902 injection, according to a Shanghai bourse filing on Thursday.The drug will be tested as a treatment for metastatic castration-resistant prostate cancer and other advanced solid tumors.The pharmaceutical company's Shanghai shares rose 2% during the morning trade.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["02696","BK0060","BK0096","BK1161","02196","BK0012","BK0175","BK1515","BK0187","BK0028","HK0000165453.HKD","HK0000320223.HKD","BK0239","BK1191","BK0188","HK0000320264.USD","BK1593","HK0000306701.USD","HK0000306685.HKD","BK0183","600196","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1174291047","title":"Fosun Pharma Subsidiary Passes GMP Compliance Inspection","url":"https://stock-news.laohu8.com/highlight/detail?id=1174291047","media":"Stock News","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1174291047?lang=en_us&edition=fundamental","pubTime":"2026-06-17 17:00","pubTimestamp":1781686827,"startTime":"0","endTime":"0","summary":"Fosun Pharma (SHSE: 600196) has announced that its controlling subsidiary, Shanghai Henlius Biopharmaceutical Co., Ltd., recently received a \"Drug GMP Compliance Inspection Notification Letter\" from...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0012","BK0028","BK0239","600196","BK0187","BK0183","BK0188","BK0196","BK0096","BK1593","BK1191","BK1515","BK0175","02196","BK0060"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"listingDate":"1998-08-07","address":"上海市普陀区曹杨路510号9楼","stockEarnings":[{"period":"1week","weight":0.0094},{"period":"1month","weight":-0.0335},{"period":"3month","weight":-0.1699},{"period":"6month","weight":-0.1518},{"period":"1year","weight":-0.094},{"period":"ytd","weight":-0.1518}],"companyName":"上海复星医药(集团)股份有限公司","boardCode":"AI0027","perCapita":"--","boardName":"医药制造业","registeredCapital":"267042万元","compareEarnings":[{"period":"1week","weight":-0.0029},{"period":"1month","weight":0.0063},{"period":"3month","weight":0.0369},{"period":"6month","weight":0.0316},{"period":"1year","weight":0.1887},{"period":"ytd","weight":0.0316}],"survey":"　　上海复星医药(集团)股份有限公司的主营业务是制药、医疗器械与医学诊断、医疗健康服务，并通过参股国药控股覆盖到医药商业领域。公司的主要产品是抗肿瘤及免疫调节核心产品、抗感染核心产品、代谢及消化系统核心产品、心血管系统核心产品、中枢神经系统核心产品、原料药和中间体核心产品。根据工信部中国医药工业信息中心颁布的“2024年度中国医药工业百强企业榜单”，本集团位列第5位。此外，在ESG方面，复星医药于报告期内荣登2025《财富》ESG影响力榜单，成为唯一入选该榜单的中国医药企业。根据MSCI于2025年7月公布的ESG年度评级结果，本集团MSCIESG评级提升至AA级。在AI领域，复星医药凭借自主研发的PharmAID医药智能平台荣获福布斯“2025中国人工智能科技创新场景应用企业TOP10”。","serverTime":1782918779166,"listedPrice":7.15,"stockholders":"0人","compareStock":{"symbol":"000001.SH","name":"SSE Comp"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.(600196),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.(600196) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.,600196,Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.股票,Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.股票老虎,Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.股票老虎国际,Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.行情,Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.股票行情,Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.股价,Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.股市,Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.股票价格,Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.股票交易,Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.股票购买,Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.(600196),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.(600196) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction